trimethadione 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2751 | 127-48-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.50 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 279.44 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 25, 1946 | FDA | ABBVIE |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N03AC02 | NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Oxazolidine derivatives |
| FDA PE | N0000008486 | Decreased Central Nervous System Disorganized Electrical Activity |
| CHEBI has role | CHEBI:35623 | anticonvulsants |
| CHEBI has role | CHEBI:176497 | geroprotectors |
| MeSH PA | D000927 | Anticonvulsants |
| MeSH PA | D002491 | Central Nervous System Agents |
| FDA EPC | N0000175753 | Anti-epileptic Agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Absence seizure | indication | 79631006 | |
| Epilepsy | indication | 84757009 | DOID:1826 |
| Retinal disorder | contraindication | 29555009 | DOID:5679 |
| Proteinuria | contraindication | 29738008 | DOID:576 |
| Lymphadenopathy | contraindication | 30746006 | |
| Eaton-Lambert syndrome | contraindication | 56989000 | DOID:0050214 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Disorder of optic nerve | contraindication | 77157004 | DOID:1891 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Lupus erythematosus and erythema multiforme-like syndrome | contraindication | 238926009 | |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Porphyria | contraindication | 418470004 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Voltage-dependent T-type calcium channel subunit alpha-1G | Ion channel | BLOCKER | WOMBAT-PK | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018714 | VUID |
| N0000147020 | NUI |
| D00392 | KEGG_DRUG |
| 4018714 | VANDF |
| C0041038 | UMLSCUI |
| CHEBI:9727 | CHEBI |
| CHEMBL695 | ChEMBL_ID |
| DB00347 | DRUGBANK_ID |
| D014293 | MESH_DESCRIPTOR_UI |
| 5576 | PUBCHEM_CID |
| 1714 | INN_ID |
| 7316 | IUPHAR_LIGAND_ID |
| R7GV3H6FQ4 | UNII |
| 10827 | RXNORM |
| 1652 | MMSL |
| 5630 | MMSL |
| d00945 | MMSL |
| 001627 | NDDF |
| 386170005 | SNOMEDCT_US |
| 70732003 | SNOMEDCT_US |
Pharmaceutical products:
None